Prominent brainstem and cerebellar involvement in multiple sclerosis with psoriasis

Multiple Sclerosis

Volumn 15, Issue 6, 2009, Pages 763-766

  Ganesvaran, G ^a   Greer, J M ^b   Pender, Michael P ^a,b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Brainstem; Cerebellum; HLA; Multiple sclerosis; Psoriasis

Indexed keywords

BETA INTERFERON; GENOMIC DNA; HLA DR ANTIGEN; HLA DR4 ANTIGEN; HLA DR7 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; BRAIN STEM INJURY; CEREBELLUM DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HLA TYPING; HOMOZYGOSITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE SCLEROSIS; PATIENT IDENTIFICATION; PSORIASIS;

ADOLESCENT; ADULT; BRAIN STEM; CEREBELLUM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-DR ANTIGENS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PSORIASIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 66149170106     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509103612     Document Type: Article

References (12)

1. Pender, MP, Greer, JM. Immunology of multiple sclerosis. Curr Allergy Asthma Rep 2007; 7: 285-292.
2. Ghoreschi, K, Weigert, C, Rócken, M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007; 25: 574-580.
3. Henderson, RD, Bain, CJ, Pender MP., The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J Clin Neurosci 2000; 7: 434-437.
4. Barcellos LF, Kamdar, BB, Ramsay, PP, et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: A descriptive study. Lancet Neurol 2006; 5: 924-931.
5. Ramagopalan, SV, Dyment, DA, Valdar, W, et al. Autoimmune disease in families with multiple sclerosis: A population-based study. Lancet Neurol 2007; 6: 604-610.
6. Kurtzke, JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
7. Roxburgh, RHSR, Seaman, SR, Masterman, T, et al. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.
8. Polman, CH, Reingold, SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005; 58: 840-846.
9. Gudjonsson, JE, Elder, JT. Psoriasis: Epidemiology. Clin Dermatol 2007; 25: 535-546.
10. Greer, JM, Csurhes, PA, Muller, DM, Pender, MP. Correlation of blood T cell and antibody reactivity to myelin proteins with HLA type and lesion localization in multiple sclerosis. J Immunol 2008; 180: 6402-6410.
11. Schmitt-Egenolf, M, Boehncke, W-H, Ständer, M, Eiermann, TH, Sterry, W. Oligonucleotide typing reveals association of type 1 psoriasis with the HLA-DRB1*0701/2, -DQA1*0201, -DQB1*0303 extended haplotype. J Invest Dermatol 1993; 100: 749-752.
12. DeLuca, GC, Ramagopalan, SV, Herrera, BM, et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A 2007; 104: 20896-20901.